drugset / Trial / NCT04990349

Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock

NCT04990349

Phase 3 Completed 60 enrolled Centre Hospitalier Universitaire de Besancon
RandomizedParallel-groupOpen-labelTreatment

Summary

Because of dual oxygenation and oxygenator performance (PO2 postoxygenator up to 500 mmHg), hyperoxemia (PaO2 \> 150 mmHg) is frequent in veino-arterial ECMO, especially in the lower part of the body, which is mainly oxygenated by ECMO. By enhancing oxygen free radicals' production, hyperoxemia might favor gut, kidney and liver dysfunction. We hypothesize that targeting an extracorporeal normoxemia (i.e. PO2 postoxygenator between 100 and 150 mmHg) will decrease gut, kidney and liver dysfunctions, compared to a liberal extracorporeal oxygenation.

Timeline

Start
2022-01-09
Primary completion
2023-11-10
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxygen gas Unknown

Indications